TRD_18_026-09_0004_L.jpg

Simon Nebel

Over the past 20 years, Simon was involved in 4 Private Equities vehicles in healthcare and renewable energy, as Managing Partner at Aravis, with a total of more than CHF 250M assets under management. The funds invested in more than 20 private companies of which 16 were in healthcare. The invested start-up and growth capital has enabled the development of new diagnostics and treatments in oncology, cardiovascular, infectious and respiratory diseases. 

11 out of the 16 healthcare companies were acquired by large pharmaceutical, diagnostic or medical device companies or were listed publicly. Moreover, many of the start-up companies have managed to strike strategic partnerships with blue chip life sciences companies such as Novartis, Roche, Boerhinger Ingelheim and AstraZeneca. 

Simon currently sits on the board of directors of Marinomed (Vienna), Bird Rock Bio (La Jolla), SynAffix (Oss, Netherlands) and Northern Bitcoin (Frankfurt).

Simon holds a master and PhD in structural biology from the Biozentrum, University of Basel as well as an MBA with distinction from the London Business School.